About Kiyatec
Kiyatec is a Healthcare company based in Pendleton (United States) founded in 2005 by Matt Gevaert. Kiyatec is focused on revolutionizing cancer care through predictive platforms. It operates on a HealthTech model. Kiyatec has raised $29.49 million across 13 funding rounds from investors including LabCorp, Bruker and HHS. Kiyatec offers products and services including 3D Predict Platform, 3D Predict Tumor-Specific, 3D Predict Glioma, and KIYA-Predict. Its focus areas include Biotechnology and Cancer Diagnostics. Its competitors include Guardant Health, GRAIL and Natera; 3 of its 3 listed competitors have raised funding.
Company details
Kiyatec is engaged in developing advanced 3D predictive platforms for cancer care. The company operates within the healthcare and biotechnology sector, specializing in tumor-specific diagnostics and personalized treatment solutions. Platforms such as 3D Predict and KIYA-Predict are designed to assist oncologists, neuro-oncologists, and other healthcare professionals in making informed treatment decisions. Services are extended to patients and caregivers, aiming to improve outcomes in oncology, particularly for complex cases like glioma. The company is headquartered in Greenville, United States, and collaborates with drug development professionals and pharmaceutical researchers to advance cancer therapy solutions.
- Headquarters Pendleton, United States
- Founders Matt Gevaert
- SectorsHealthcare
- Phone•••• ••••
- Website kiyatec.com
- Social LinkedIn X
- Legal Name Kiyatec
- Total Equity Funding$29.49M (USD)
in 13 rounds
- InvestorsLabCorp
& 10 more
Products & Services of Kiyatec
Kiyatec offers a comprehensive portfolio of products and services, including 3D Predict Platform, 3D Predict Tumor-Specific, 3D Predict Glioma, and KIYA-Predict.
A platform for tumor-specific cancer treatment prediction.
Tumor-specific analysis for personalized cancer therapy solutions.
Specialized glioma analysis for targeted cancer treatment options.
Predictive tool for oncology treatment planning and decisions.
Funding Insights of Kiyatec
Kiyatec has successfully raised a total of $29.49M across 13 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $29.49M
- Total Rounds 13
- First Round $200,000
(Feb 2009)
- Investors Count 11
Latest 10 of 13 funding rounds of Kiyatec with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2025 | Series C | – | MBD Biotech | – | |
| Oct 2024 | $250,000 | Series C | – | – | – |
| May 2023 | Series C | – | – | ||
| Dec 2022 | $18.06M | Series C | – | Bruker | |
| Apr 2021 | $2.5M | Series B | – | – | |
| Jan 2020 | Series B | – | Esperante | – | |
| Mar 2019 | $5.33M | Series B | – | VentureSouth | |
| Oct 2016 | $3.15M | Series A | – | VentureSouth | – |
| Nov 2015 | Series A | – | SCRA | – | |
| Aug 2015 | $1.98M | Grant | – | – |
11 investors in total: 11 institutional.
Investors in Kiyatec
Kiyatec has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include LabCorp, Bruker and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Philanthropic capital is invested to advance brain tumor treatments. | braintumorinvestmentfund.org | Newton, United States | ||
Venture capital investments are made in healthcare and fintech sectors. | seaeventures.com | Boston, United States | ||
Early-stage ventures in the Southeast are supported by VentureSouth. | 2014 | venturesouth.vc | Greenville, United States | |
Esperante is focused on innovative life science investments. | esperante.com | Hoofddorp, Netherlands | ||
Startups are accelerated across sectors by SCRA. | 1983 | scra.org | United States | |
PE firm investing in Europe and the US | nmtcapital.com | Norwell, United States | ||
Private foundation of Northeast Florida focused on the healthcare sector | 2002 | sontagfoundation.org | ||
Diversified research instrument systems are manufactured and supplied. | 1960 | bruker.com | United States | |
Provider of laboratory tests for physicians | 1969 | labcorp.com | Burlington, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Kiyatec
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kiyatec
9 people are tracked at Kiyatec (5 in leadership, 4 in board & advisors).
| Name | Role | Group |
|---|---|---|
Matt Gevaert | Co-Founder | Leadership |
Wes Carr | Chief Financial Officer | Leadership |
Matthew R. Gevaert | CEO & Co-Founder | Leadership |
Lillia M. Holmes | Chief Operations Officer | Leadership |
Tessa Desrochers | Chief Scientific Officer | Leadership |
Bruce Nash | Board Member | Board & advisors |
Christopher Brotherton | Board Member | Board & advisors |
Jason Robart | Board Member | Board & advisors |
Robert Silverman | Chairman | Board & advisors |
Complete people profiles for Kiyatec
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Kiyatec
3 dated milestones of Kiyatec across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Kiyatec is founded.
- Funding First funding round of $200K.
- Funding Latest funding round, Series C,.
Competitors of Kiyatec
Kiyatec has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Natera.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health |
Detailed competitors of Kiyatec
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kiyatec
The website of Kiyatec (kiyatec.com) receives about 2.6K visits a month.
- Monthly visits2.6K
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Kiyatec (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kiyatec
Complete news archive for Kiyatec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kiyatec
Kiyatec was founded in 2005 and raised its 1st funding round 4 years after it was founded.
Kiyatec is headquartered in Pendleton, United States. It is registered at Pendleton, Oregon, United States.
Kiyatec is a funded company, having raised a total of $29.49M across 13 funding rounds to date. The company's 1st funding round was a Grant of $1.98M, raised on Feb 2009.
Kiyatec is engaged in developing advanced 3D predictive platforms for cancer care. The company operates within the healthcare and biotechnology sector, specializing in tumor-specific diagnostics and personalized treatment solutions. Platforms such as 3D Predict and KIYA-Predict are designed to assist oncologists, neuro-oncologists, and other healthcare professionals in making informed treatment decisions. Services are extended to patients and caregivers, aiming to improve outcomes in oncology, particularly for complex cases like glioma. The company is headquartered in Greenville, United States, and collaborates with drug development professionals and pharmaceutical researchers to advance cancer therapy solutions.
Kiyatec's top competitors include Guardant Health, GRAIL and Natera.
Kiyatec offers 3D Predict Platform, 3D Predict Tumor-Specific, 3D Predict Glioma, and KIYA-Predict.
Kiyatec has 11 investors. Key investors include LabCorp, Bruker, HHS, SCRA, and The Sontag Foundation.
Kiyatec operates through Kiyatec.